Medicare Part D Overpayments: Reconciliation, Identification and Return

Whistleblower Justice Network

Medicare Part D overpayment return depends on what a sponsor knew after the annual reconciliation deadline. A rebate left out of the report can leave Medicare paying more than it owes. If you work in plan finance, pharmacy benefit management or payment reporting, you may know where the account stopped matching the money: a rebate left out, a drug event left uncorrected, or a certification signed after someone raised the problem. That connection is where we start.

When Is a Part D Overpayment Identified?

A Part D sponsor identifies an overpayment when it knowingly receives or keeps money it is not entitled to after applicable reconciliation. The Centers for Medicare & Medicaid Services explains in its final overpayment rule that the sponsor must report and return the identified overpayment within 60 days.

For this rule, applicable reconciliation turns on the later of the relevant annual deadlines for prescription drug event data and direct and indirect remuneration data. Those are the PDE and DIR submissions familiar to plan reporting staff. The agency says annual reconciliation data is due within six months of the contract year’s end. The data deadline and the later payment adjustment are distinct events.

Knowing includes deliberately looking the other way or recklessly disregarding whether the information is true. An internal warning, the response to it and the next submission can therefore matter together. The useful question is what the sponsor understood about its reporting and payment when it decided what to correct.

The agency explains that corrected PDE and DIR data let it calculate and recover the overpayment through its global reopening process. The sponsor supplies the correction. The agency calculates the money to recover.

How PDE and DIR Data Change Medicare’s Payment

Medicare Part D payment reconciliation connects PDE and DIR data to the federal money a sponsor receives. The Centers for Medicare & Medicaid Services pays estimates in advance, then uses the year’s reported information to determine the payment adjustment. The pharmacy transaction supplies part of that account.

The sponsor’s approved bid, enrollment and risk information affect its direct subsidy. Reinsurance and low-income cost-sharing subsidies have their own payment inputs.

A PDE describes a drug event’s covered costs and payer amounts. DIR captures price concessions that reduce drug costs, including manufacturer rebates. Accepted records, rejected submissions, adjustments and deletions show which version of the drug-event data reached the agency.

The 2025 Part D payment instructions show why the rebate report matters. The agency uses DIR with PDE cost data to reduce allowable reinsurance costs. The remaining DIR enters the calculation of risk-corridor costs, where the government and the plan share specified gains or losses around a target. Leaving a concession out can leave taxpayers paying more for the same health care.

This reaches beyond a missing rebate check. Someone classifying a payment as a service fee can affect whether it reduces the reported drug cost. Someone handling a pharmacy reversal can see whether the event was corrected in the sponsor’s reporting. The payment story runs through both the commercial transaction and what the sponsor told Medicare about it.

The Congressional Research Service’s 2011 report, Medicare Program Integrity: Activities to Protect Medicare from Payment Errors, Fraud, and Abuse, separated inaccurate drug-event records from errors in the payment system and subsidy status. Bad PDE data affected reinsurance and low-income cost-sharing payments. For an insider following healthcare payments, the distinction gives us a specific question: which payment did the bad data change?

Part D Reconciliation Versus A/B Refund Rules

Part D reconciliation and Medicare Parts A and B refund rules run on different clocks. A sponsor’s drug-event and rebate reports follow their own deadlines and payment years.

Under the amendment effective January 1, 2025, a timely, good-faith investigation of related A/B overpayments can pause the return deadline. The pause ends when the investigation and total calculation finish, or at 180 days after initial identification, whichever comes first.

Part D has no matching investigation suspension. The final rule explains why: the sponsor supplies corrected data, and the agency calculates the resulting overpayment.

The lookback differs too. A/B uses six years from receipt. Part D uses the six most recent completed payment years. That makes the payment year and correction history central to a Part D inquiry.

The PDE, DIR and Certification Record

The annual certification links the sponsor’s payment data to what its leadership said was accurate. The Centers for Medicare & Medicaid Services attestation memorandum for contract year 2025 shows what that signature covers.

It required the sponsor’s chief executive, financial or operating officer to sign electronically. The sponsor certified its PDE data, Summary DIR and other information used for allowable reinsurance and risk-corridor costs as accurate, complete and truthful. The attestation expressly acknowledged that the information would obtain federal reimbursement. Contractors that generate claims data for the sponsor have certification duties too.

For that payment year, the attestation covered retroactive adjustments received by May 29, 2026, with signatures due August 18, 2026. An attachment could describe a potential or identified PDE error already reported to the agency and being corrected, its magnitude and the expected resolution timeline.

The memorandum distinguishes Summary DIR used for payment from Detailed DIR used for the branded-drug manufacturer fee process. A file called DIR is only useful once we know which report it is and what the agency used it for.

For an insider, the error attachment can be especially revealing. It can put the concern, its estimated size and prior notice to the agency beside the officer’s signature. We examine those records together with the reporting history and the warnings and payment records behind the discrepancy.

Medicare Part D Data Correction and Retained Funds

A corrected drug-event file and the funds a Part D sponsor retains tell different parts of the payment story. A revised internal worksheet shows work inside the company. The accepted correction, reconciliation result and account entry show whether that work reached the federal payment.

We follow that connection when a reporting practice repeats across drug events or payment years. Which records used the disputed treatment? Which corrections reached the agency? What did the sponsor know while the treatment continued? We connect the reporting decision to the money it affected, with the insider who knows how the business operated.

When Rebates Were Reported as Service Fees

Elixir Insurance Company and Rite Aid agreed to pay $101 million in a civil settlement announced in July 2024. The government alleged that manufacturer rebates had been reported as bona fide service fees even though the manufacturers had not negotiated to pay those fees. The alleged classification kept rebates from reducing the costs reported to Medicare.

The case began with a whistleblower who had served as vice president of finance and then chief underwriting officer. His complaint alleged that Elixir reported $58 million to $65 million in retained rebates as service fees each year since 2016. It alleged that the pharmacy benefit manager, EPS, kept those rebates. The complaint challenged the supposed work behind the fee:

The Retained Rebates are not in exchange for any bona fide, itemized services actually performed by EPS on behalf of any pharmaceutical manufacturer.

United States ex rel. Rzeszutko v. Rite Aid Corporation et al., whistleblower complaint, paragraph 83

The complaint also alleged that the concern reached Rite Aid’s chief executive and financial officers, who expressed concern but allowed the practice to continue. The government later alleged that Elixir knew the retained rebates did not qualify for the service-fee treatment.

A service fee. For services the whistleblower said never happened. We see a label doing the work: turning a drug discount owed to Medicare into money the pharmacy benefit manager kept, according to the complaint. The contract, the rebate, the report and the internal warning each tell part of the story. That is why a retained-payment inquiry reaches the person who chose the classification as well as the person who submitted the file.

When You Know Why the Account Stayed Wrong

A plan finance analyst, reporting employee or pharmacy benefit manager employee may see where the data changed, who approved the treatment and whether the correction reached the agency. We connect that firsthand account to the certification, applicable reconciliation and retained payment. Your knowledge of how the business handled a warning gives the documents their context.

Knowingly keeping money owed to Medicare past the return deadline is the basis of a False Claims Act overpayment case. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Correction Never Reached the Money

If you know why a Part D sponsor kept reporting the wrong costs or kept money after the problem was identified, speak with our whistleblower experts about the reporting decision. We work beside you to build a case from that knowledge and bring in Medicare Part D whistleblower lawyers who understand sponsor reporting and reconciliation. Bring us the decision behind the wrong numbers so we can build your strongest Part D whistleblower case together.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365